Rebalancing the Immune System to Fight Type 1 Diabetes

🔬 New study by #HelmholtzMunich, #DZD & Goethe University Frankfurt shows vidofludimus calcium may delay #Type1Diabetes by rebalancing immune cells.

👉 Read more: t1p.de/n6s0g

@daniellab.bsky.social @diabresearch-dzd.bsky.social @goetheuni.bsky.social

Fighting Metabolic Diseases Through Immune Modulation

Immune Modulation in Metabolic Disease

A study from #HelmholtzMunich & #DZD uncovers how #Tregs link immunity & #metabolism, paving the way for immune-based therapies for #obesity & #Type2Diabetes.
Learn more:
👉 t1p.de/4uebn

#Immunology #DiabetesResearch

Inspiring Careers – Insights on Female Leadership

#ScienceNeedsHer
Inspiring Careers – Insights on Female Leadership

#HelmholtzMunich wrapped up its #AwarenessMonth #WomenAtHelmholtzMunich with the event "Inspiring Careers – Insights on Female Leadership" at Salon Luitpold in Munich.

👉 t1p.de/9jw3p

Photos: ©Milos Jakobi I Helmholtz Munich

Obesity is complex. Say no to discrimination. Stand up against bullying. End the stigma.

Today is #WorldObesityDay.

#Obesity is a complex condition and each individual faces distinct needs & challenges.

A healthier society is possible only if we prioritize community support & stand up against discrimination and stigma 🔗bit.ly/3SAcdeE

More reasons to celebrate today! 👏 Our PhD student Sandra Dirschl won the Jury's Choice Award at the Three-Minute Thesis Competition organized by @www.helmholtz-munich.de's Research School for Diabetes. Congratulations, Sandra! 🏆

Happy International Day of Women and Girls In Science! On this day, I'm proud to acknowledge the creativity, hard work and contributions of all the women in the TDI team. Thank you for your ideas and your wonderful work!

#WomenAtHelmholtzMunich
This February, we’re kicking off an awareness month for our outstanding #WomenInScience! 👏

👉 Check out inspiring thoughts, careers & leadership journeys of female researchers at #HelmholtzMunich:
t1p.de/mddsr

🌟Stay tuned & learn why #ScienceNeedsHer!
#InspiringWomen

Technische Assistenz - BTA/CTA/MTA (m/w/d)

Job alert! We're looking for a Technical Assistant for our team, with experience in molecular and cell biology techniques (e.g., PCR, ELISA, flow cytometry), and skills in managing mouse lines (FELASA certification is a plus).

Learn more and apply here:

T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics Abdelfattah et al. developed an engineering platform (T-Switch) for the creation, modification, and high-throughput profiling of T cell receptors (TCRs) to desired targets, particularly self-antigens....

Engineering T cells with capability for a switch in specificity
www.cell.com/immunity/ful... for better homing agents, to improve safety and efficacy vs cancer and other emerging T cell interventions

Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma - Nature Immunology Tumor-antigen-specific CD8+ T cells are generally thought to help fight against cancer, but here the authors identify a subpopulation of CD8+ T cells that are associated with a poor clinical outcome i...

More #evidence for the existence of #CD8 #Regulatory #Tcells www.nature.com/articles/s41... Check our previous paper also> #KIR+CD8+ #T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19 | Science www.science.org/doi/10.1126/...

Excited to participate in next week's workshop on T cell diversity at the Bayerische Akademie der Wissenschaften @badw.de and present our work on regulatory T cells in diabetes. Don't miss it!

#Tregs #Immunology #DiabetesResearch @www.helmholtz-munich.de

Cancer escapes immunotherapies by mutating its surface, meaning even groundbreaking #CARTCell therapies fail too often. But what if #GenerativeAI could design CAR-T with de novo binders faster, targeting resistant tumors? 🧵 www.biorxiv.org/content/10.1... (1)

Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️

So how can we ever achieve #gender #equality?

We discuss various strategies in this #Cell Commentary

#WomeninSTEM

www.cell.com/cell/fulltex...
🧵 1/

T cells that have not undergone MHC selection can bind soluble antigens, such as proteins or peptides, without the need for MHC presentation. 😱😱www.sciencedirect.com/science/article/pii/S107...

Adipose tissue retains an epigenetic memory of obesity after weight loss - Nature Stable epigenetic changes indicate the existence of an obesogenic memory in mouse adipocytes that primes cells for pathological responses in an obesogenic environment and potentially contributes to th...

🧬 New in @Nature: Our team found that fat cells keep a “memory” of their previous obese state even after weight loss, helping explain why maintaining weight loss is so challenging. Excited to share this work!!

www.nature.com/articles/s41...

To make our fantastic CITE-seq data set of postnatal thymocytes accessible to the community, we have launched a shiny app for interactive exploration. Check it out! 👇
ccgg.ugent.be/shiny/htsa_t...
Moreover, scRNA-seq and Visium spatial data can be found at cellxgene.cziscience.com/collections/...

Hello, #Bluesky community! 🌟
We are TDI (Type 1 Diabetes Immunology) at #HelmholtzMunich. Our research focuses on understanding the role of #Tregs in autoimmune diseases such as #Type1Diabetes. Excited to reconnect with peers here and forge new connections with #immunologists worldwide!🙌

Friends, the second #immunology starter pack filled in 3 days! I started a third to help folks new to BlueSky rebuild their network

Below are the links

If you're an immunologist and I have missed you so far, let me know 🧪

go.bsky.app/PY5tCas

go.bsky.app/FmERUoD

go.bsky.app/6aT6qDS

Starter pack for #Type1Diabetes and #Islet Research

Comment if you want to be added to the list 👇

Would love to be added. Thank you!

Thank you for your effort! Could you please add me? Thank you!

Thank you for your effort in rebuilding connections! Could you please ad me too?